Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose

Preliminary study

M. Falconi, C. Contro, M. Ballabio, C. Bassi, R. Salvia, P. Pederzoli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background. Total parenteral nutrition and somatostatin or analogues represent a consolidated therapeutic approach for external fistulas, a frequent complication of major pancreatic surgery. Aims. To establish the effects of the somatostatin analogue lanreotide on exocrine pancreatic secretion. Methods. Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial. The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial. Results. In the seven patients completing the study, the 24-h output volume was 208.6±41.3 and 253.9±72.4 ml after lanreotide and placebo, respectively. During the first 6 hours values were 48.1± 14.7 and 77.6±21.4 ml (p = 0.02). No significant difference between treatments was detected in the qualitative composition of 24-h pancreatic secretion, although bicarbonate secretion remained lower after the active drug at all the observation intervals. Peak lanreotide levels were detected 15-30 min after drug injection. Clinical and laboratory tolerability was good. Conclusions. Lanreotide induced a statistically significant reduction in the output volume with respect to placebo in the first 6 hours after administration, but not thereafter. The present results encourage a new study to be undertaken in a larger sample and with a multiple dosing scheme of treatment.

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalDigestive and Liver Disease
Volume34
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Placebos
Somatostatin
Cutaneous Fistula
Pancreaticoduodenectomy
Total Parenteral Nutrition
Subcutaneous Injections
Bicarbonates
Pharmaceutical Preparations
Cross-Over Studies
Therapeutics
Observation
lanreotide
Injections
Neoplasms

Keywords

  • Exocrine pancreas
  • Lanreotide

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose : Preliminary study. / Falconi, M.; Contro, C.; Ballabio, M.; Bassi, C.; Salvia, R.; Pederzoli, P.

In: Digestive and Liver Disease, Vol. 34, No. 2, 2002, p. 127-132.

Research output: Contribution to journalArticle

Falconi, M. ; Contro, C. ; Ballabio, M. ; Bassi, C. ; Salvia, R. ; Pederzoli, P. / Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose : Preliminary study. In: Digestive and Liver Disease. 2002 ; Vol. 34, No. 2. pp. 127-132.
@article{74392de15ed546dc9dbf19d597a23615,
title = "Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: Preliminary study",
abstract = "Background. Total parenteral nutrition and somatostatin or analogues represent a consolidated therapeutic approach for external fistulas, a frequent complication of major pancreatic surgery. Aims. To establish the effects of the somatostatin analogue lanreotide on exocrine pancreatic secretion. Methods. Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial. The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial. Results. In the seven patients completing the study, the 24-h output volume was 208.6±41.3 and 253.9±72.4 ml after lanreotide and placebo, respectively. During the first 6 hours values were 48.1± 14.7 and 77.6±21.4 ml (p = 0.02). No significant difference between treatments was detected in the qualitative composition of 24-h pancreatic secretion, although bicarbonate secretion remained lower after the active drug at all the observation intervals. Peak lanreotide levels were detected 15-30 min after drug injection. Clinical and laboratory tolerability was good. Conclusions. Lanreotide induced a statistically significant reduction in the output volume with respect to placebo in the first 6 hours after administration, but not thereafter. The present results encourage a new study to be undertaken in a larger sample and with a multiple dosing scheme of treatment.",
keywords = "Exocrine pancreas, Lanreotide",
author = "M. Falconi and C. Contro and M. Ballabio and C. Bassi and R. Salvia and P. Pederzoli",
year = "2002",
doi = "10.1016/S1590-8658(02)80242-0",
language = "English",
volume = "34",
pages = "127--132",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose

T2 - Preliminary study

AU - Falconi, M.

AU - Contro, C.

AU - Ballabio, M.

AU - Bassi, C.

AU - Salvia, R.

AU - Pederzoli, P.

PY - 2002

Y1 - 2002

N2 - Background. Total parenteral nutrition and somatostatin or analogues represent a consolidated therapeutic approach for external fistulas, a frequent complication of major pancreatic surgery. Aims. To establish the effects of the somatostatin analogue lanreotide on exocrine pancreatic secretion. Methods. Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial. The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial. Results. In the seven patients completing the study, the 24-h output volume was 208.6±41.3 and 253.9±72.4 ml after lanreotide and placebo, respectively. During the first 6 hours values were 48.1± 14.7 and 77.6±21.4 ml (p = 0.02). No significant difference between treatments was detected in the qualitative composition of 24-h pancreatic secretion, although bicarbonate secretion remained lower after the active drug at all the observation intervals. Peak lanreotide levels were detected 15-30 min after drug injection. Clinical and laboratory tolerability was good. Conclusions. Lanreotide induced a statistically significant reduction in the output volume with respect to placebo in the first 6 hours after administration, but not thereafter. The present results encourage a new study to be undertaken in a larger sample and with a multiple dosing scheme of treatment.

AB - Background. Total parenteral nutrition and somatostatin or analogues represent a consolidated therapeutic approach for external fistulas, a frequent complication of major pancreatic surgery. Aims. To establish the effects of the somatostatin analogue lanreotide on exocrine pancreatic secretion. Methods. Eight patients, undergoing pancreaticoduodenectomy for malignancy, were enrolled in the trial. The volume and composition of pancreatic secretion were evaluated after one single subcutaneous injection of lanreotide 0.5 mg or placebo in a randomised, double-blind cross-over trial. Results. In the seven patients completing the study, the 24-h output volume was 208.6±41.3 and 253.9±72.4 ml after lanreotide and placebo, respectively. During the first 6 hours values were 48.1± 14.7 and 77.6±21.4 ml (p = 0.02). No significant difference between treatments was detected in the qualitative composition of 24-h pancreatic secretion, although bicarbonate secretion remained lower after the active drug at all the observation intervals. Peak lanreotide levels were detected 15-30 min after drug injection. Clinical and laboratory tolerability was good. Conclusions. Lanreotide induced a statistically significant reduction in the output volume with respect to placebo in the first 6 hours after administration, but not thereafter. The present results encourage a new study to be undertaken in a larger sample and with a multiple dosing scheme of treatment.

KW - Exocrine pancreas

KW - Lanreotide

UR - http://www.scopus.com/inward/record.url?scp=0036185983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036185983&partnerID=8YFLogxK

U2 - 10.1016/S1590-8658(02)80242-0

DO - 10.1016/S1590-8658(02)80242-0

M3 - Article

VL - 34

SP - 127

EP - 132

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 2

ER -